Online inquiry

IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14734MR)

This product GTTS-WQ14734MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in B cell acute lymphoblastic leukemia (B cell ALL), Refractory B-lineage non-Hodgkin lymphoma research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ14734MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15254MR IVTScrip™ mRNA-Anti-phosphatidylserine, Tarvacin ch3G4(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA Tarvacin ch3G4
GTTS-WQ13982MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ1789MR IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ADCT-402
GTTS-WQ2683MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 785
GTTS-WQ6780MR IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DS-8201
GTTS-WQ1233MR IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABR-217620
GTTS-WQ9832MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA JTX-2011
GTTS-WQ14354MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA RG7716
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW